IMPORTANT
SAFETY
INFORMATION FULL
PRESCRIBING
INFORMATION PATIENT
INFORMATION MEDICAL
INFORMATION PATIENT
SITE

Xiidra® patient case studies

Take an in-depth look at actual patients who have been treated with Xiidra, including the symptoms they reported, evaluation techniques, and ultimately the treatment regimen that helped bring symptom relief to them.

sticky line
Xiidra patient case studies
sticky line

Xiidra® patient case studies

Take an in-depth look at actual patients who have been treated with Xiidra, including the symptoms they reported, evaluation techniques, and ultimately the treatment regimen that helped bring symptom relief to them.

IN THIS SECTION

IN THIS SECTION

melanie portfolio

Patient case study:

Melanie, a prior user of artificial tears

Melanie suffered from the symptoms of dry eye disease for years before going to her eye doctor. After some diagnostic evaluation and consultation with her eye doctor, Melanie decided to try Xiidra—which brought her relief.

Check out Melanie's case
Check out Melanie's case
art'Tee portrait

Patient case study:

Ar’Tee, a patient who addressed his dry eye symptoms head-on

Ar’Tee experienced his dry eye symptoms as an acute event that started just months before seeking treatment. But further evaluation of his eyes showed the signs of dry eye disease and an underlying cause of his symptoms. When Ar’Tee began treatment with Xiidra, he was able to find symptom relief early in his treatment journey.

Explore Ar’Tee's case
Explore Ar’Tee's case

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for Full Prescribing Information.